CMS Adopts Final Rule Phasing Out Fax and Mail for Health Care Claims Attachments
The Centers for Medicare & Medicaid Services (CMS) issued a final rule on national standards for electronic claims attachments and signatures,...
The U.S. Food and Drug Administration (FDA) formally rescinded its final rule regulating laboratory-developed tests as medical devices, and regulatory review is now pending. Because the FDA did not move to appeal this decision, the rescission is essentially a formality.
The recission comes following the decision filed March 31 in the U.S. District Court in the Eastern District of Texas, which ruled the FDA exceeded its authority and subsequently vacated the final rule. The FDA did not appeal this decision.
Once the Office of Information and Regulatory Affairs completes the regulatory review, a formal notice will be posted to the Federal Register within 60 days.
Sources:
https://www.reginfo.gov/public/do/eoDetails?rrid=1044563
https://documents.cap.org/documents/ldt-courtruling-03-31-2025.pdf
https://www.cap.org/advocacy/latest-news-and-practice-data/august-12-2025#story3
CMS Clarifies CLIA Certification Requirements for Remote Cytology
The Centers for Medicare & Medicaid Services (CMS) recently clarified Clinical Laboratory Improvement Act (CLIA) certification requirements for...
TELCOR Promotions - April 2026
Lincoln, NE – April 2026 TELCOR is proud to announce the promotion ofJoni Fitzgerald to Senior Revenue Cycle Supervisor, Natalie Helkenn to RCS...